Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 olpasiran trial in adults with elevated lipoprotein(a) and atherosclerotic cardiovascular disease
NL-OMON52533Phase 2Completed
- Sponsor
- Amgen
- Start
- Nov 2020
- Modality
- Vaccine mRNA → mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atherosclerotic disease and lipoprotein(a) hyperlipoproteinemia (Lp(a)) comparing Olpasiran with Placebo (2 arms). Primary endpoint: Percent change in lipoprotein(a) from baseline at week 36. Started Nov 2020; status: completed.
02
Drugs
olpasiran
03
Conditions
atherosclerotic diseaselipoprotein(a) hyperlipoproteinemia (Lp(a))
Beyond the preview
Go deeper on NL-OMON52533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52533.